CRISPR Breakthrough: First Gene-Editing Treatment Outside the US Launches in Bahrain
CRISPR technology — a groundbreaking gene-editing innovation — has taken a major step forward, now making its clinical debut outside the United States. In a recent MedCram video, Dr. Roger Seheult walks us through the science behind this revolutionary approach and shares exciting news from the Kingdom of Bahrain, where CRISPR has been successfully used to treat sickle cell disease for the first time internationally.
What Is CRISPR?
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing tool adapted from a bacterial defense system. It allows scientists to cut and modify DNA with remarkable precision. By using a combination of RNA guides and the Cas9 enzyme, researchers can target specific genetic sequences and either disrupt faulty genes or insert functioning ones. This technology holds immense potential for treating inherited genetic disorders.
FDA Approvals and Sickle Cell Treatment
In late 2023, the FDA approved the first CRISPR-based gene therapies, including Casgevy and Lyfgenia, for treating sickle cell disease — a painful and life-limiting condition caused by a mutation in the hemoglobin gene.
-
Casgevy (exagamglogene autotemcel) works by editing a regulatory gene (BCL11A), boosting production of fetal hemoglobin (HbF), which doesn’t sickle like the mutated adult form.
-
Lyfgenia (lovotibeglogene autotemcel) modifies the patient’s own stem cells to produce a corrected version of adult hemoglobin (HbA) that resists sickling.
Both approaches involve collecting the patient’s own stem cells, editing them in the lab, wiping out the faulty bone marrow with chemotherapy, and reinfusing the edited cells.
Remarkable Results in Clinical Trials
Studies published in the New England Journal of Medicine show dramatic outcomes:
-
Patients experienced a sharp drop in vaso-occlusive crises, the painful episodes characteristic of sickle cell disease.
-
Hospitalizations and transfusion requirements also plummeted, reflecting improved quality of life and long-term disease management.
A Global Milestone: CRISPR Treatment in Bahrain
Bahrain has now become the first country outside the United States to administer CRISPR-based treatment for sickle cell disease. This historic achievement showcases Bahrain’s commitment to integrating cutting-edge medical innovation into its healthcare system.
Dr. Seheult commended Bahrain’s forward-thinking medical leadership, noting the country’s impressive infrastructure, dedication to technology, and inclusive, interfaith community environment. During a recent visit, the MedCram team met with public health officials, toured high-tech simulation labs, and witnessed firsthand the nation’s commitment to advanced medical care.
As Bahrain’s Minister of Health, Dr. Jalila Bent Al-Sayed, stated:
“This milestone exemplifies Bahrain’s commitment to integrating global medical innovations from our national healthcare strategy… positioning Bahrain as a hub for innovative medical care.”
Why This Matters
CRISPR is no longer just a theoretical or research-focused tool — it’s becoming a real-world treatment for diseases previously thought untreatable. Bahrain’s adoption of this therapy signals not only its leadership in healthcare innovation but also a broader global shift toward accessible gene-editing therapies.
Watch the full MedCram video for a detailed explanation of the CRISPR mechanism, a review of the clinical trial data, and exclusive insights from Dr. Seheult’s trip to Bahrain.
LINKS / REFERENCES: Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US (Fintech) | https://www.fintechfutures.com/press-…
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (FDA) | https://www.fda.gov/news-events/press…
New CRISPR-based sickle cell treatment, explained (STAT) | 
• New CRISPR-based sickle cell treatment, ex… Genome Editing with CRISPR-Cas9 (McGovern) | • Genome Editing with CRISPR-Cas9 CASGEVY® is a CRISPR/Cas9-modified autologous CD34+ cellular gene therapy (Casgevy) | https://www.casgevyhcp.com/sickle-cel…
Lyfgenia (Lyfgenia) | https://www.lyfgenia.com/
What is CRISPR? (UMass Chan) | https://www.umassmed.edu/rti/biology/…
Exagamglogene Autotemcel for Severe Sickle Cell Disease (NEJM) | https://www.nejm.org/doi/full/10.1056…
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease (NEJM) | https://www.nejm.org/doi/full/10.1056…